315 related articles for article (PubMed ID: 32044149)
1. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation.
M A; Chatterjee S; A P; S M; Davuluri S; Ar AK; T A; M P; Cs P; Sinha M; Chugani A; R VP; Kk A; R S J
Immunobiology; 2020 May; 225(3):151907. PubMed ID: 32044149
[TBL] [Abstract][Full Text] [Related]
2. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.
Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490
[TBL] [Abstract][Full Text] [Related]
4. Differential chemokine, chemokine receptor and cytokine expression in Epstein-Barr virus-associated lymphoproliferative diseases.
Ohshima K; Karube K; Hamasaki M; Tutiya T; Yamaguchi T; Suefuji H; Suzuki K; Suzumiya J; Ohga S; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1367-78. PubMed ID: 12952231
[TBL] [Abstract][Full Text] [Related]
5. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in
Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
[TBL] [Abstract][Full Text] [Related]
8. Reduced frequency of cytotoxic CD56
Pánisová E; Lünemann A; Bürgler S; Kotur M; Lazarovici J; Danu A; Kaulfuss M; Mietz J; Chijioke O; Münz C; Busson P; Berger C; Ghez D; Azzi T
Cancer Immunol Immunother; 2022 Jan; 71(1):13-24. PubMed ID: 33993319
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Flavell JR; Baumforth KR; Wood VH; Davies GL; Wei W; Reynolds GM; Morgan S; Boyce A; Kelly GL; Young LS; Murray PG
Blood; 2008 Jan; 111(1):292-301. PubMed ID: 17720884
[TBL] [Abstract][Full Text] [Related]
10. Innate immune responses against Epstein Barr virus infection.
Chijioke O; Azzi T; Nadal D; Münz C
J Leukoc Biol; 2013 Dec; 94(6):1185-90. PubMed ID: 23812328
[TBL] [Abstract][Full Text] [Related]
11. Role for early-differentiated natural killer cells in infectious mononucleosis.
Azzi T; Lünemann A; Murer A; Ueda S; Béziat V; Malmberg KJ; Staubli G; Gysin C; Berger C; Münz C; Chijioke O; Nadal D
Blood; 2014 Oct; 124(16):2533-43. PubMed ID: 25205117
[TBL] [Abstract][Full Text] [Related]
12. Role of human natural killer cells during Epstein-Barr virus infection.
Münz C
Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312
[TBL] [Abstract][Full Text] [Related]
13. The immune response to primary EBV infection: a role for natural killer cells.
Williams H; McAulay K; Macsween KF; Gallacher NJ; Higgins CD; Harrison N; Swerdlow AJ; Crawford DH
Br J Haematol; 2005 Apr; 129(2):266-74. PubMed ID: 15813855
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection.
Zhang Y; Ohyashiki JH; Takaku T; Shimizu N; Ohyashiki K
Br J Cancer; 2006 Feb; 94(4):599-608. PubMed ID: 16449999
[TBL] [Abstract][Full Text] [Related]
17. Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.
Mueller NE; Lennette ET; Dupnik K; Birmann BM
Int J Cancer; 2012 Jun; 130(12):2886-91. PubMed ID: 21805472
[TBL] [Abstract][Full Text] [Related]
18. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ.
Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A
Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151
[TBL] [Abstract][Full Text] [Related]
19. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line.
Tsuge I; Morishima T; Morita M; Kimura H; Kuzushima K; Matsuoka H
Clin Exp Immunol; 1999 Mar; 115(3):385-92. PubMed ID: 10193407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
